Vertex Pharmaceuticals: latest news - GoINPHARMA
Friday, 19 October 2018 - 3:48

Vertex Pharmaceuticals

Vertex, Genomics sign development agreement

Vertex Pharmaceuticals, one of the most successful biotechs in the world, and Britain-based Genomics plc have announced that they have signed a three-year collaboration agreement, extendable to five years, to use human genetics and AI to improve drug discovery for…

Two biotechs to keep an eye on

Two small biotechs are drawing attention from analysts and investors-Amryt Pharma and Eloxx Pharmaceuticals. Amryt Pharma was established as little as three years ago, but differently from other biotech companies it already has a product on the market, which generates…

Good news for Vertex again: Symdeko approved as cystic fibrosis treatment

Vertex has reported that the FDA has approved Symdeko (tezacaftor/ivacaftor and ivacaftor) that, once on the market, will cost $292,000 annually and will contribute $100-200m to the group’s financial results as early as this year. Vertex’s management expects the group…

Vertex is still one of the top M&A targets

Analysts and healthcare experts have been looking at Vertex Pharmaceuticals as one of the next M&A targets for months. Chances for the Boston-based group to be taken over have become stronger than ever in the last days. Indeed, Vertex has…

An analysis of the potential Gilead – Vertex merger

Investors have long hoped that Gilead carries out a major acquisition, allowing the California-based biotech group to create a shift portfolio to offset the steady loss in revenue and profit due to the sharp sales decline in its hepatitis-C business….

The incredible growth of biotech industry

The American Society of Clinical Oncology Annual Meeting ended few days ago without producing any sharp rise in shares, except for Loxo Oncology, which presented data causing shares to soar by 40%. The financial community was relieved that no untoward…

2016 results from seven companies expected next week

BioPharmaDive has provided an interesting report of what we can expect from the pharma and biotech companies which will report their results next week. Such remarks are significant, especially following declarations by the US President-elect. As for Johnson & Johnson,…